Citigroup Reiterates Rating on Glaukos Corporation $GKOS
Key Points
- Citigroup now rates Glaukos Corporation ($GKOS) "buy" with a $162 target.
- Citigroup's $162 price target implies 24.48% upside from Glaukos Corporation's ($GKOS) current $130.14 share price.
- The Street's average $GKOS price target is $197.15 (Strong Buy).
- $GKOS last traded around $130.14.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Citigroup reiterated its rating on Glaukos Corporation ($GKOS) to a "buy" rating in a recent research note and set a price target of $162, a 24.48% upside from the current price.
Glaukos Corporation Stock Down 27.6%
Shares of Glaukos Corporation ($GKOS) traded around $130.14 on Saturday, down 27.6% for the day.
Glaukos Corporation Earnings
Analysts Set New Price Targets
About Glaukos Corporation
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Get Glaukos Corporation alerts
New 13F filings, insider trades, and analyst moves on $GKOS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.